Dr. Suzanne Topalian on the PD-1 Targeted Therapy BMS-936558
by on Sunday, June 3rd, 2012 | No Comments
Suzanne Topalian, MD, Professor of Surgery and Oncology at the Johns Hopkins University School of Medicine, discusses early-stage results of the targeted immune agent BMS-936558, a co-inhibitor of the programmed death-1 (PD-1) receptor that is expressed by activated T cells. Find out more at www.onclive.com
Continue reading here: Dr. Suzanne Topalian on the PD-1 Targeted Therapy BMS-936558